Derepressing of STAT3 and USP7 contributes to resistance of DLBCL to EZH2 inhibition

Diffuse large B-cell lymphoma is the most common subtype of lymphoma, representing ∼25 % of non-Hodgkin lymphoid malignancies. EZH2 is highly expressed in Diffuse large B-cell lymphoma and ∼22 % of patients contain EZH2 mutations. EZH2 have been studied as a potential therapeutic target for a decade...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Chenyun, Zhou, Wenbin, Jin, Xiaoxia, Zhou, Haining
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565777/
https://www.ncbi.nlm.nih.gov/pubmed/37829803
http://dx.doi.org/10.1016/j.heliyon.2023.e20650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565777/
https://www.ncbi.nlm.nih.gov/pubmed/37829803
http://dx.doi.org/10.1016/j.heliyon.2023.e20650

Ejemplares similares